In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.
about
Functional, biophysical, and structural bases for antibacterial activity of tigecyclineA multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].Alternative strategies for proof-of-principle studies of antibacterial agentsDaptomycin in paediatrics: current knowledge and the need for future researchTigecycline: first of a new class of antimicrobial agentsPharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model.Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrationsTelavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogensShort-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.Use of ribotyping to retrospectively identify methicillin-resistant Staphylococcus aureus isolates from phase 3 clinical trials for tigecycline that are genotypically related to community-associated isolates.Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam.Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infectionsA randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infectionsTracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing.Antimicrobial therapy of methicillin resistant Staphylococcus aureus infection.Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infectionIn vivo efficacy of anuran trypsin inhibitory peptides against staphylococcal skin infection and the impact of peptide cyclizationDaptomycin.Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria.Activity of daptomycin against recent North American isolates of Streptococcus pneumoniaeMulticenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp.Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections.Daptomycin - a novel antibiotic against Gram-positive pathogens.Tigecycline: a new glycylcycline for treatment of serious infections.Tigecyclin--the first glycylcycline to undergo clinical development: an overview of in vitro activity compared to tetracycline.Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline.Tigecycline: a novel glycylcycline antibiotic.Oritavancin--an investigational glycopeptide antibiotic.In vitro activities of tigecycline against the Bacteroides fragilis group.Comparative in vitro activities of AC98-6446, a novel semisynthetic glycopeptide derivative of the natural product mannopeptimycin alpha, and other antimicrobial agents against gram-positive clinical isolates.Update on daptomycin: the first approved lipopeptide antibiotic.Correlation of cell membrane lipid profiles with daptomycin resistance in methicillin-resistant Staphylococcus aureus.Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Tigecycline does not prolong corrected QT intervals in healthy subjects.Establishing the role of tigecycline in an era of antimicrobial resistance.Daptomycin antibiotic lock therapy in a rat model of staphylococcal central venous catheter biofilm infectionsHistory and evolution of antibiotic resistance in coagulase-negative staphylococci: Susceptibility profiles of new anti-staphylococcal agents.Antibacterial and osteo-stimulatory effects of a borate-based glass series doped with strontium ions.In vitro activity of daptomycin and tigecycline against coagulase-negative staphylococcus blood isolates from bone marrow transplant recipients.
P2860
Q24548264-6EE2226D-2F3C-4CFF-9FC1-7974E72FBE55Q24813784-B6758113-CBCB-4A69-BBC8-3D63E010418CQ26850895-FCEC197E-C1F7-495F-91FA-0E0DFACF8070Q27006038-B89CE050-9E51-4ACC-85E5-D6288685B02AQ28253736-FFB96EC9-551F-4018-9463-AF8E56638062Q33555775-64A0FE03-AF42-4096-B829-BABDDEC53DBFQ33722056-D1ADC5B7-EF89-42D5-8F3B-9CB36E9AAC1BQ33788308-48CF545E-841D-4B5B-A8C6-2B5D1C04C2ADQ33883648-4C08B477-4C0D-4855-BC5F-C675FC6E8FCDQ34123752-60C1A259-BED1-41F5-9349-6DCB3B216932Q34123811-AA90E776-A95D-4730-9745-A1500A3ECDBDQ34352287-D0A79CAB-3480-488A-88AD-BDCE25F6B4C1Q34474973-8035FF23-5B84-4562-A128-1DC283C561C6Q34630593-E0713F7C-B825-407A-8517-C0491772F421Q35058095-2551AC01-D6EF-4677-9D59-70760A1B7015Q35109773-ACA03F24-0E3D-4341-815B-6DD21C4A736FQ35169096-925F3F95-07A7-45AE-A541-783852A853E7Q35637066-1C772B52-4579-4997-A2D9-2DBD145B1687Q35637071-580D29D4-1701-4781-BEC1-2C7DDF526733Q35685343-C3447B05-EB8C-4F38-84CA-82FA2FBB79E9Q35690304-E8650955-7480-43C8-99FE-6692A5651CCFQ35871928-3BDECC73-5601-4ACE-93F4-5146EAF19CCFQ35925535-5F554AD8-2687-4BC7-97D7-E72BB01DE3E3Q36218312-172E0519-9E51-4AC1-99DD-AE8B71E5AC5CQ36312068-D68DC2FF-E94D-424F-9A33-EFCA3DFD0930Q36312071-5D8C6C0A-EB9E-462C-9FA9-F2B34DCF3FB5Q36379330-475B0EEC-0F21-4C1A-A11B-B3275D7970E6Q36426011-9E6A0978-A775-4D4A-B706-110CFA2CED02Q36490533-AF135054-EAA4-4010-8C5F-FC1A4F46962DQ36492132-0EA40FEA-D1EC-44DF-BEC2-1CDE6D7F5BC8Q36521880-AE6E933A-6A7B-45DA-960B-1F9A0E0A6B79Q36558432-3AB7EA5B-9DE4-4FC0-BC76-63D157360A82Q36663656-50214BE7-FAEA-43F3-8A84-0F97A0B966ECQ36718474-F885BC52-EB5C-4975-9566-A957FC690DC2Q36757583-5CB12765-7956-434F-A62B-0DD6D9BC363DQ37291328-28337D76-91B0-4BBD-B213-533D5DDA9B61Q38282725-DEEC3642-06A0-46FB-B871-DE5831335527Q38536137-FE0C4316-7EFB-4B09-ADF8-2DC8BE5E627AQ38736002-65724B84-02D1-4FF7-B6DA-F93FE656654DQ39147856-6DFBF45B-042E-4ABE-AD67-1F21A675217E
P2860
In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
In vitro and in vivo activitie ...... stant gram-positive pathogens.
@ast
In vitro and in vivo activitie ...... stant gram-positive pathogens.
@en
In vitro and in vivo activitie ...... stant gram-positive pathogens.
@nl
type
label
In vitro and in vivo activitie ...... stant gram-positive pathogens.
@ast
In vitro and in vivo activitie ...... stant gram-positive pathogens.
@en
In vitro and in vivo activitie ...... stant gram-positive pathogens.
@nl
prefLabel
In vitro and in vivo activitie ...... stant gram-positive pathogens.
@ast
In vitro and in vivo activitie ...... stant gram-positive pathogens.
@en
In vitro and in vivo activitie ...... stant gram-positive pathogens.
@nl
P2093
P2860
P1476
In vitro and in vivo activitie ...... stant gram-positive pathogens.
@en
P2093
Peter J Petersen
Steven J Projan
Timothy M Murphy
William J Weiss
P2860
P304
P356
10.1128/AAC.46.8.2595-2601.2002
P407
P577
2002-08-01T00:00:00Z